RxDoctor Payments DataLook up a doctor →

Molly Szerlip, MD

Interventional Cardiology · Plano, TXNPI 1902849631

Payments from drug & device makers

$1,472,880in general payments, 2019–2025

Across 904 payments — averaging $1629.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1.1M
  • Shockwave Medical, Inc$144K
  • Medtronic$136K
  • Boston Scientific$65K
  • Abbott$38K
  • Bayer$13K
  • plus $21K from 40 others
$2,566in research payments, 2019–2025

Across 6 payments — averaging $427.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$3K
  • Abiomed$66

What the payments were for

  • Consulting fees$38,25629%
  • Speaking & faculty fees$43,68334%
  • Grants$1350%
  • Travel & lodging$21,08216%
  • Food & beverage$26,42120%
  • Other$2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,472,880 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$241,925
Medicare patients
739
Services billed
1,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$111,853
Repatha SureclickEvolocumab43$57,484
EntrestoSacubitril/Valsartan41$53,461
JardianceEmpagliflozin40$42,641
XareltoRivaroxaban18$22,851
Ranolazine ErRanolazine23$2,925
Metoprolol Succinate133$1,898
Rosuvastatin Calcium126$1,720
Losartan Potassium54$803
Nifedipine ErNifedipine39$702
Atorvastatin Calcium83$670
Olmesartan Medoxomil31$565
ClopidogrelClopidogrel Bisulfate46$547
Valsartan15$496
Metoprolol Tartrate50$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$111,85399 claims
NovartisEntresto$253$53,46141 claims
Boehringer IngelheimJardiance$231$42,64140 claims
Johnson & JohnsonXarelto$343$22,85118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →